3SBio to Market Japanese Pruritis Treatment in China

3SBio of Shenyang in-licensed China rights to a pruritis (itching) treatment developed by Japan 's Toray Industries. TRK-820 is a highly selective opioid receptor agonist that is intended to treat the itching that accompanies chronic liver disease and peritoneal dialysis. 3SBio will commercialize the oral disintegration formulation of the drug to facilitate dosing in patients who have difficulty swallowing. The company will make upfront and milestone payments to Toray, though no details were disclosed. More details.... Stock Symbol: (HK: 1530) Share this with colleagues: // //